Discover the truth about hormones & your health in myth-busting podcast series

 

Hormones: The Inside Story, the podcast series uncovering the facts about hormones and health with an expert-led, myth-busting and entertaining format, is back for a second series on 8 November 2021. Hormones affect growth, sleep, body fat, fertility and almost every aspect of our daily lives and health. Sadly, the mainstream media is brimming with misinformation and potentially dangerous advice from a host of non-experts and dubious commercial enterprises.

 

Building on the huge success of last year’s debut series, the Society for Endocrinology and First Create The Media have just released series two, which continues examining the stories and the science behind hormones, cutting through the myths and misinformation, providing real facts and enabling you to make better decisions about your health.

With the help of presenter Georgia Mills, this series uncovers the truth about how hormones affect our growth, weight, mood, how we age and our declining fertility. Speaking with leading experts, she'll be finding out about the controversies around the male menopause, fasting and weight loss, whether there really is a fertility crisis and if you can beat the aging process or boost your happiness by hacking your hormones. Tune in to learn how monkey testicles could link to the fountain of youth, why Irish giants are not just the stuff of legend, the secrets of lengthy prairie vole ‘romance’ and how brushing your teeth could save your life.

 

“Educational and entertaining. Interesting and relevant content brilliantly presented, with a great balance of expert input. Informative, interesting, accessible.”

Apple review

 

The podcast style is informative, with a warm, funny side, aimed at engaging people with the real science about hormones. Each episode is framed around a common question about a hormone-based hot topic:

 

 

“Perfectly paced. ‘Hormones’ isn’t a subject that would normally detain me for too long, but this series kept me entertained and informed throughout.”

Apple review

 

1. Can I take hormones to make me taller?

2. Does when I eat affect my body weight?

3. Can I hack my hormones to beat aging?

4. Menopause vs. manopause – are they equivalent?

5. Is there really a fertility crisis?

6. Can I hack my hormones to improve my mood?

 

To listen and subscribe, simply search for 'Hormones: The Inside Story' on Apple Podcasts, Google Podcasts, Spotify or wherever you like to listen. You can also follow us on Twitter @Soc_Endo and use #InsideHormones to keep the conversation going.

The Society for Endocrinology is a registered charity and membership organisation that supports scientists, clinicians and nurses who work with hormones. It also engages policy-makers, journalists, patients and the public with hormone science to encourage informed health decisions, and to demonstrate the value of endocrinology to the wider world. This very important project, overseen by the Society’s Public Engagement Committee, contributes to its mission of better informing the public about the role hormones play in all aspects of human life, as well as building awareness of its informative and public-friendly website, You & Your Hormones.

 

“Love this podcast! The host has a really clever way of breaking down the information from the experts to make it fun and easy to understand!”

Apple review

  

Hormone EPO shown to improve brain sharpness in patients with depression and bipolar disorder

A study has found that EPO (erythropoietin) – best known as a performance-enhancing drug in sport – may improve cognitive functioning in patients suffering from bipolar disorder or depression. This raises hope for the first long-term treatment for this problem, which affects hundreds of millions of patients throughout the world. The work is presented today at the ECNP conference in Vienna*.

The hormone EPO, mostly produced by the kidney, is essential for the production of red blood cells. EPO gives the blood a greater capacity to carry oxygen, and it is this characteristic which makes it attractive as a performance-enhancing drug (the cyclist Lance Armstrong admitted to using EPO to improve physical performance). Medically, recombinant EPO is used for the treatment of anaemia.

Most people think of disorders such as bipolar disorder and depression as conditions which affect mood, but in reality they also affect cognitive function - how quickly and how well a brain functions. This slow-down in thinking can have serious effects on sufferers, making it more difficult to retain a job, pass an exam, or maintain a relationship. Now a group of Danish Scientists have discovered that EPO can help restore cognitive function in patients suffering from these mental disorders.

In two randomized controlled trials, the researchers assessed cognitive function in 79 patients suffering from depression or bipolar disorder. They assigned 40 of the patients to be given EPO for 9 weeks, with the remaining 39 being given a placebo. They found that EPO had beneficial effects on patients’ completion of a range of cognitive tests, including tests on verbal memory, attention span, and planning ability. Tests showed that this improvement was maintained for at least 6 weeks after treatment finished (the longest follow-up time in the trials). 

Lead researcher, Dr Kamilla Miskowiak said:

“EPO treated patients showed a five times greater cognitive improvement from their individual baseline levels compared with placebo treated patients. EPO-treated patients showed 11% improvement while placebo treated patients improved only by 2%. This effect of EPO on cognition was maintained six weeks after patients had completed their treatment”.

In an interesting twist, it was found that patients who performed poorly in neuropsychological tests showed remarkably greater cognitive benefits when given EPO. Dr Miskowiak, commented:

“This is interesting, as it means that we may be able to target patients for EPO treatment –and perhaps other future cognition treatments - based on how they do on neuropsychological tests”.

She continued

“We need bigger studies to confirm that the effects we have seen can be replicated, to confirm dosage, frequency of use and so on. EPO is already used medically, so we know quite a lot about safety. Although EPO is generally safe if patients’ red blood cell levels are controlled regularly, there are certain groups for whom the risk of blot clots is too high – for example people who smoke or who have previously had blood clots. So although these results hold out great promise, EPO treatment is not ready to be rolled out as a treatment just yet and may not be for everyone”.

The WHO estimates that around 350 million people suffer from depression, with a further 60 million suffering from bipolar disorder**, but the drugs normally used to treat depression and bipolar disorders don’t have any major effect on cognition. Up to 70% of patients in remission from bipolar disorder, and up to 40% in remission from depression continue to have cognitive problems. Currently there is no available effective treatment to target cognitive problems in these patients.

Commenting, Professor Eduard Vieta (Chair of the Department of Psychiatry and Psychology at the University of Barcelona Hospital Clinic and treasurer of the ECNP) said:

“The results of this study, albeit preliminary, give hope to people suffering from mood disorders and associated neurocognitive symptoms. Those symptoms are now recognized as a core part of affective disorders and are not appropriately tackled by the currently available pharmacological armamentarium, despite their close association with relevant clinical outcomes such as the ability to return to work”.

Hormone treatment in transgender persons could shed light on role of sex hormones in bone density

Male-to-female (MtF) transgender persons have a greater increase in bone mineral density than female-to-male (FtM) persons in their first year of hormone treatment. The research, presented at the European Congress of Endocrinology in Munich, helps scientists further understand the roles sex hormones play on bone development and maintenance in both sexes.

As the number of people seeking gender reassignment treatment continues to increase globally, there is an ever-greater need for scientists and clinicians to understand the effects of cross-gender hormonal treatment on the human body. Within the first year of gender transition, applicants are treated with sex hormones: MtF persons receive oestrogen, whilst FtM persons receive testosterone.

It is known that oestrogen increases bone density, however, whilst it is known that testosterone increases bone size, its effects on bone density are still unknown. To further investigate, a research team from VU University Medical Centre in Amsterdam completed an observational study of 188 adults undergoing hormone treatment for gender reassignment. Bone mineral density was measured both before and after one year of hormone treatment; the results showed that MtF persons receiving oestrogen had an average increase in spine bone density of 3.72%, compared to only a 1% increase in FtM persons receiving testosterone.

These results confirm our understanding that oestrogen increases bone density, and suggest that testosterone does not, or does so to a lesser extent. Interestingly, in FtM transgender persons who were post-menopausal with low pre-treatment oestrogen levels, bone density of the spine was seen to increase by 4.5% following testosterone treatment.

“As this increase was only found in those with low pre-treatment oestrogen levels, it might suggest that in biological adult women (pre-menopause) testosterone primarily affects bone density through its conversion into oestrogen,” said Dr Chantal Wiepjes, lead author of the study.

“Our next steps will be to investigate what the long-term effects of hormone treatment are on bone density. Patients undergoing hormone therapy routinely have bone density scans, which might give them the impression that hormone treatment can have adverse effects on their bones. Therefore, a more solid molecular long-term understanding of the changes may reassure them,” continued Dr Chantal Wiepjes. “I also think transitioning patients should be aware that the changes caused by these hormones aren’t just external – their internal structure changes too”.

As well as improving understanding of treatments within the transgender community, by studying the effects of cross-sex hormone treatment, the team hopes to more clearly understand the role of oestrogen in biological males, and the role of testosterone in biological females.

Whilst it should be noted that the observational study did not compare results to a control group, the team feel that differences seen in post-menopausal FtM persons suggest that it is unlikely the changes in bone density seen were merely due to age or timing.

  

European Hormone Meeting 1 -3 October 2015, Barcelona‏

The 54^th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) will be held 1 – 3 October in Barcelona, Spain. The ESPE annual scientific meeting is recognised worldwide as a meeting of high scientific and educational quality. This year's theme is “Improving patient care: a pluridisciplinary dialogue”.

Three embargoed press releases will be sent out ahead of the conference covering ground-breaking research in the following areas:

·         A link between asthma medication and stunted growth

·         A novel technique for the production of insulin-producing cells for the treatment of diabetes

·         A large scale study which links increased height with an increased risk of cancer

The European Society for Paediatric Endocrinology (ESPE) is a truly international organisation aiming to improve the clinical care of children and adolescents with endocrine conditions, including diabetes, through research and education.